230 related articles for article (PubMed ID: 36787937)
41. Blood Pressure, Chronic Kidney Disease Progression, and Kidney Allograft Failure in Kidney Transplant Recipients: A Secondary Analysis of the FAVORIT Trial.
Malhotra R; Katz R; Weiner DE; Levey AS; Cheung AK; Bostom AG; Ix JH
Am J Hypertens; 2019 Aug; 32(9):816-823. PubMed ID: 31179500
[TBL] [Abstract][Full Text] [Related]
42. Systolic Blood Pressure Time in Target Range and Major Adverse Kidney and Cardiovascular Events.
Buckley LF; Baker WL; Van Tassell BW; Cohen JB; Alkhezi O; Bress AP; Dixon DL
Hypertension; 2023 Feb; 80(2):305-313. PubMed ID: 36254738
[TBL] [Abstract][Full Text] [Related]
43. Assessment of Long-term Benefit of Intensive Blood Pressure Control on Residual Life Span: Secondary Analysis of the Systolic Blood Pressure Intervention Trial (SPRINT).
Vaduganathan M; Claggett BL; Juraschek SP; Solomon SD
JAMA Cardiol; 2020 May; 5(5):576-581. PubMed ID: 32101262
[TBL] [Abstract][Full Text] [Related]
44. Kidney Disease, Hypertension Treatment, and Cerebral Perfusion and Structure.
Kurella Tamura M; Gaussoin S; Pajewski NM; Zaharchuk G; Freedman BI; Rapp SR; Auchus AP; Haley WE; Oparil S; Kendrick J; Roumie CL; Beddhu S; Cheung AK; Williamson JD; Detre JA; Dolui S; Bryan RN; Nasrallah IM;
Am J Kidney Dis; 2022 May; 79(5):677-687.e1. PubMed ID: 34543687
[TBL] [Abstract][Full Text] [Related]
45. Dipping Status, Ambulatory Blood Pressure Control, Cardiovascular Disease, and Kidney Disease Progression: A Multicenter Cohort Study of CKD.
Borrelli S; Garofalo C; Gabbai FB; Chiodini P; Signoriello S; Paoletti E; Ravera M; Bussalino E; Bellizzi V; Liberti ME; De Nicola L; Minutolo R
Am J Kidney Dis; 2023 Jan; 81(1):15-24.e1. PubMed ID: 35709922
[TBL] [Abstract][Full Text] [Related]
46. Intensive blood pressure lowering and the risk of new-onset diabetes in patients with hypertension: a post-hoc analysis of the STEP randomized trial.
Yang R; Zhu Y; Xu M; Tao Y; Cong W; Cai J
Eur J Prev Cardiol; 2023 Aug; 30(10):988-995. PubMed ID: 37036035
[TBL] [Abstract][Full Text] [Related]
47. Assessment of Risk of Harm Associated With Intensive Blood Pressure Management Among Patients With Hypertension Who Smoke: A Secondary Analysis of the Systolic Blood Pressure Intervention Trial.
Scarpa J; Bruzelius E; Doupe P; Le M; Faghmous J; Baum A
JAMA Netw Open; 2019 Mar; 2(3):e190005. PubMed ID: 30848803
[TBL] [Abstract][Full Text] [Related]
48. Effects of blood pressure on renal and cardiovascular outcomes in Asian patients with type 2 diabetes and overt nephropathy: a post hoc analysis (ORIENT-blood pressure).
Imai E; Ito S; Haneda M; Harada A; Kobayashi F; Yamasaki T; Makino H; Chan JC
Nephrol Dial Transplant; 2016 Mar; 31(3):447-54. PubMed ID: 26152402
[TBL] [Abstract][Full Text] [Related]
49. Heterogeneity of Treatment Effects for Intensive Blood Pressure Therapy by Individual Components of FRS: An Unsupervised Data-Driven Subgroup Analysis in SPRINT and ACCORD.
Wu Y; Bai J; Zhang M; Shao F; Yi H; You D; Zhao Y
Front Cardiovasc Med; 2022; 9():778756. PubMed ID: 35187120
[TBL] [Abstract][Full Text] [Related]
50. Estimated GFR and the Effect of Intensive Blood Pressure Lowering After Acute Intracerebral Hemorrhage.
Zheng D; Sato S; Arima H; Heeley E; Delcourt C; Cao Y; Chalmers J; Anderson CS;
Am J Kidney Dis; 2016 Jul; 68(1):94-102. PubMed ID: 26948991
[TBL] [Abstract][Full Text] [Related]
51. Blood pressure reduction in diabetes: lessons from ACCORD, SPRINT and EMPA-REG OUTCOME.
Sarafidis PA; Lazaridis AA; Ruiz-Hurtado G; Ruilope LM
Nat Rev Endocrinol; 2017 Jun; 13(6):365-374. PubMed ID: 28106149
[TBL] [Abstract][Full Text] [Related]
52. Effect of intensive blood pressure lowering on cardiovascular outcomes based on cardiovascular risk: A secondary analysis of the SPRINT trial.
Attar A; Sayadi M; Jannati M
Eur J Prev Cardiol; 2019 Feb; 26(3):238-245. PubMed ID: 30256671
[TBL] [Abstract][Full Text] [Related]
53. Effect of Achieved Systolic Blood Pressure on Cardiovascular Outcomes in Patients With Type 2 Diabetes: A Population-Based Retrospective Cohort Study.
Wan EYF; Yu EYT; Chin WY; Fung CSC; Fong DYT; Choi EPH; Chan AKC; Lam CLK
Diabetes Care; 2018 Jun; 41(6):1134-1141. PubMed ID: 29592967
[TBL] [Abstract][Full Text] [Related]
54. The Benefits of Intensive Versus Standard Blood Pressure Treatment According to Fine Particulate Matter Air Pollution Exposure: A Post Hoc Analysis of SPRINT.
Al-Kindi SG; Brook RD; Bhatt U; Brauer M; Cushman WC; Hanson HA; Kostis J; Lash JP; Paine R; Raphael KL; Rapp S; Tamariz L; Wright JT; Rajagopalan S;
Hypertension; 2021 Mar; 77(3):813-822. PubMed ID: 33517683
[TBL] [Abstract][Full Text] [Related]
55. Creatinine Rise During Blood Pressure Therapy and the Risk of Adverse Clinical Outcomes in Patients With Type 2 Diabetes Mellitus.
Collard D; Brouwer TF; Peters RJG; Vogt L; van den Born BH
Hypertension; 2018 Dec; 72(6):1337-1344. PubMed ID: 30571235
[TBL] [Abstract][Full Text] [Related]
56. Relationship between blood pressure and kidney diseases in large randomized controlled trials: secondary analyses using SPRINT and ACCORD-BP trials.
Wang L; Pezeshkian K; Rayamajhi S; Herzallah K; Al-Abcha A; Olomu A; Kelly-Blake K; Yu E; Wang DH
J Hum Hypertens; 2021 Oct; 35(10):859-869. PubMed ID: 33093616
[TBL] [Abstract][Full Text] [Related]
57. Effects of intensive versus standard blood pressure control on domain-specific cognitive function: a substudy of the SPRINT randomised controlled trial.
Rapp SR; Gaussoin SA; Sachs BC; Chelune G; Supiano MA; Lerner AJ; Wadley VG; Wilson VM; Fine LJ; Whittle JC; Auchus AP; Beddhu S; Berlowitz DR; Bress AP; Johnson KC; Krousel-Wood M; Martindale-Adams J; Miller EC; Rifkin DE; Snyder JK; Tamariz L; Wolfgram DF; Cleveland ML; Yang M; Nichols LO; Bryan RN; Reboussin DM; Williamson JD; Pajewski NM;
Lancet Neurol; 2020 Nov; 19(11):899-907. PubMed ID: 33098800
[TBL] [Abstract][Full Text] [Related]
58. Acute Declines in Renal Function during Intensive BP Lowering and Long-Term Risk of Death.
Ku E; Ix JH; Jamerson K; Tangri N; Lin F; Gassman J; Smogorzewski M; Sarnak MJ
J Am Soc Nephrol; 2018 Sep; 29(9):2401-2408. PubMed ID: 30006417
[TBL] [Abstract][Full Text] [Related]
59. Effects of Intensive Blood Pressure Control in Patients with Evident Cardiovascular Disease: An Investigation Using the SPRINT Study Data.
Vlachopoulos C; Terentes-Printzios D; Aznaouridis K; Ioakeimidis N; Xaplanteris P; Lazaros G; Tousoulis D
Curr Vasc Pharmacol; 2019; 17(3):298-306. PubMed ID: 29512468
[TBL] [Abstract][Full Text] [Related]
60. Remnant cholesterol and intensive blood pressure control in older patients with hypertension: a post hoc analysis of the STEP randomized trial†.
Yang R; Zhang J; Yu X; Yang G; Cai J
Eur J Prev Cardiol; 2024 Jun; 31(8):997-1004. PubMed ID: 38167928
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
